SCHEMBL18902145

SCHEMBL18902145

CNCC1CC(C)CC1C

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.36
SLC6A4 P31645 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20682854 1.00 HTR2C (0.36) HTR2CSLC6A4
SCHEMBL2022302 0.89
SCHEMBL19407196 0.89
SCHEMBL19715628 0.89
SCHEMBL2212908 0.89
SCHEMBL15782488 0.78 HTR2C (0.35) HTR2CSLC6A4
SCHEMBL14325292 0.76 HTR2C (0.34) HTR2CSLC6A4
SCHEMBL10110551 0.76 TP53 (0.30)
SCHEMBL10831129 0.72
SCHEMBL22811147 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023235380-A1 MACROLIDES FOR TREATING GENETIC DISEASES ZIKANI THERAPEUTICS, INC. (US) 2023-12-07 WO disclosed
WO-2021222673-A1 PROCESSES FOR THE PREPARATION OF A KINASE INHIBITOR EXELIXIS, INC. (US) 2021-11-04 WO disclosed
EP-3134084-B1 METHOD OF TREATING LUNG ADENOCARCINOMA EXELIXIS INC (US) 2021-03-17 EP disclosed
EP-2768796-B1 PROCESS FOR PREPARING QUINOLINE DERIVATIVES EXELIXIS INC (US) 2019-11-20 EP disclosed
EP-2621481-B1 DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES EXELIXIS INC (US) 2019-08-14 EP disclosed
WO-2019148044-A1 COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS EXELIXIS, INC. (US) 2019-08-01 WO disclosed
EP-2727919-B1 BENZOCYCLOHEPTANETHIOPHENE DERIVATIVES FOR ANTI-ALLERGIC REACTIONS FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO LTD (CN) 2019-05-08 EP disclosed
EP-2616442-B1 INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS INC (US) 2018-08-08 EP disclosed
EP-2909188-B1 NOVEL PROCESS FOR MAKING COMPOUNDS FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2018-03-07 EP disclosed
EP-2758057-B1 METHOD FOR TREATING OSTEOPOROSIS EXELIXIS INC (US) 2017-05-31 EP disclosed